New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin's B-cell lymphoma

(University of California - Los Angeles Health Sciences) Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA found using a bilateral attack achieves a more robust defense and helps avoid relapse.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news